A significant reduction of asthma symptoms was demonstrated. GRAZAX® reduced a combined asthma symptom score by 64%. The asthma symptoms included were: coughing, wheezing, chest tightening/shortness of breath (dyspnoea) and exercise induced symptoms. Participants in the study also experienced a 67% reduction in the number of days with asthma symptoms (median)... ALK-Abelló's Press Release -
Blog Archive
-
▼
2008
(297)
-
▼
June
(39)
- M. D. Anderson and Aureon Laboratories : to Evalua...
- Aradigm : Phase 2 Study of Inhaled Liposomal Cipro...
- Alnylam and Kyowa Hakko : Alliance for the Develop...
- Altus Pharmaceuticals : Last Patient Visit Of Triz...
- Transave : POSITIVE PHASE II RESULTS FOR ONCE-DAIL...
- Gilead : Interim 12-Month Phase III Study Results ...
- Pharmacopeia and GlaxoSmithKline Collaboration : a...
- Banner Pharmacaps : FDA Approval for Amantadine S...
- ImmunoCellular Therapeutics : Research Agreement w...
- Vitrolife : STEEN Solution approved for sales in A...
- Pharmaxis : Special Protocol Assessment with FDA f...
- FASgen : Production and Investment Agreement with ...
- Vall d’Hebron University Hospital and Cyclacel Pha...
- Ikaria : INOFLO (NITRIC OXIDE) FOR INHALATION TO B...
- Boehringer Ingelheim : to acquire Actimis Pharmace...
- SkyePharma : Second Flutiform Phase III Efficacy S...
- ALK-Abelló : GRAZAX® Demonstrates Significant Redu...
- Anesiva and Transcription Factor Therapeutics : Li...
- AstraZeneca submits an sNDA for SYMBICORT® for the...
- Critical Therapeutics : Phase II Clinical Trial fo...
- Novavax : Proprietary Method to Create SARS Vaccin...
- Jennerex Promising Results from Cancer Clinical T...
- Emphasys Medical : VENT Clinical Trial Data at ATS...
- Angiotech : completion of Bio-Seal clinical trial ...
- Bayer HealthCare and Nektar Therapeutics : Amikaci...
- Lilly : Study Showed ALIMTA (pemetrexed for injec...
- GlaxoSmithKline : New data for pazopanib – GSK’s l...
- Rosetta Genomics and M. D. Anderson to Develop a M...
- GlaxoSmithKline : New data on MAGE-A3 cancer immu...
- Pulmo BioTech : Details of the Methodology for its...
- MDS Pharma Services : Therapeutic Focus on Respira...
- DEY : Concomitant Use of Nebulized Formoterol Fuma...
- Almirall & Forest : Positive Results of Clinical S...
- Basilea Pharmaceutica : Ceftobiprole shows high cu...
- Perceptronix Medical : Early Detection Brings Hope
- TeraRecon iNtuition : at the Stanford MDCT face-of...
- Critical Outcome Technologies : Amalgamation With ...
- Dako : unique package of RTU antibodies for cancer...
- Med BioGene and University Health Network : Collab...
-
▼
June
(39)
Jun 19, 2008
ALK-Abelló : GRAZAX® Demonstrates Significant Reductions on Asthma Symptoms in Children
June 8, 2008 - At the European Academy of Allergology and Clinical Immunology (EAACI 2008) in Barcelona, ALK-Abelló presented successful results from a new clinical trial, GT-12, designed to measure the impact of GRAZAX® on allergic rhinitis and allergic asthma. GT-12 compared the effects of GRAZAX® with symptomatic medication versus symptomatic medication alone on the ability to reduce symptoms of allergic rhinitis and seasonal asthma.